Phase III NALA: Neratinib + Capecitabine vs Lapatinib + Capecitabine in HER2+ MBC Previously Treated With HER2-Targeted Therapies

May 31 - June 4, 2019; Chicago, Illinois
Neratinib + capecitabine significantly prolonged PFS vs lapatinib + capecitabine (HR: 0.76) in patients with HER2+ MBC previously treated with at least 2 lines of therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 266 KB
Released: June 7, 2019


Provided by the USF Health

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)

This activity is supported by educational grants from
Celgene Corporation
Novartis Pharmaceuticals Corporation
Puma Biotechnology

Related Content

A short slideset from Clinical Care Options covering key clinical insights for the current management of HER2-positive early and metastatic breast cancer.

Neelima Denduluri, MD, FASCO Lee Schwartzberg, MD, FACP Released: July 8, 2020

A short slideset from Clinical Care Options covering key clinical insights for the current management of HR+/HER2- advanced breast cancer.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: July 1, 2020

Slides from Neelima Denduluri, MD, FASCO: HER2-targeted TKIs and antibody-drug conjugates for HER2-positive metastatic breast cancer, from CCO

Neelima Denduluri, MD, FASCO Released: June 30, 2020

Slides from Lee Schwartzberg, MD, FACP: Optimal treatment and management of toxicities for HER2-positive early-stage breast cancer, from CCO

Lee Schwartzberg, MD, FACP Released: June 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?